For the year ending 2025-12-31, KPTI has $108,416K in assets. $401,342K in debts. $60,540K in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 60,540 | |||
| Investments | 3,204 | |||
| Accounts receivable, net | 26,178 | |||
| Inventory | 4,038 | |||
| Prepaid expenses and other current assets | 9,186 | |||
| Total current assets | 103,146 | |||
| Property and equipment, gross | 5,614 | |||
| Less accumulated depreciation and amortization | 5,510 | |||
| Property and equipment, net | 104 | |||
| Operating lease right-of-use assets | 4,548 | |||
| Restricted cash | 351 | |||
| Other assets | 267 | |||
| Total assets | 108,416 | |||
| Accounts payable | 4,003 | |||
| Accrued expenses | 64,498 | |||
| Convertible senior notes due 2025 | 0 | |||
| Senior secured term loan | 21,010 | |||
| Operating lease liabilities | 969 | |||
| Other current liabilities | 1,580 | |||
| Total current liabilities | 92,060 | |||
| Convertible senior notes due 2029 | 89,973 | |||
| Convertible senior notes due 2028 | 21,117 | |||
| Senior secured term loan, net of current portion | 94,795 | |||
| Deferred royalty obligation | 72,338 | |||
| Common stock warrants | 14,221 | |||
| Operating lease liabilities, net of current portion | 5,743 | |||
| Other liabilities | 11,095 | |||
| Total liabilities | 401,342 | |||
| Common stock, 0.0001 par value 53,333 shares authorized 18,311 and 8,413 shares issued and outstanding as of december 31, 2025 and december 31, 2024, respectively | 14 | |||
| Additional paid-in capital | 1,466,488 | |||
| Accumulated other comprehensive income (loss) | 71 | |||
| Accumulated deficit | -1,759,499 | |||
| Total stockholders' deficit | -292,926 | |||
| Total liabilities and stockholders' deficit | 108,416 | |||
Karyopharm Therapeutics Inc. (KPTI)
Karyopharm Therapeutics Inc. (KPTI)